Related Experiment Videos
Intravenous immune globulin use in Canada
Kim Hanna1, Melanie Poulin-Costello, Mark Preston
1Bayer Inc, Etobicoke, Canada. Kim.Hanna.b@bayer.com
Summary
Intravenous immune globulin (IVIG) use in Canada is high, with most off-label prescriptions deemed appropriate by guidelines. Hematologists and neurologists are the primary prescribers of IVIG.
Area of Science:
- Immunology
- Pharmacology
- Health Services Research
Background:
- Intravenous immune globulin (IVIG) is a critical therapy for various autoimmune and immune deficiency disorders.
- Understanding IVIG utilization patterns and appropriateness is essential for optimizing healthcare resource allocation.
Purpose of the Study:
- To quantify IVIG usage across different indications and medical specialties in Canada.
- To evaluate the proportion of IVIG use that aligns with labeled, appropriate off-label, and inappropriate off-label indications.
Main Methods:
- Retrospective review of IVIG dispensing data from 10 Canadian hospital blood banks (adult and pediatric sites).
- Data collected included grams dispensed, indications, prescribing specialty, and patient numbers from 1997-1999.
- Appropriateness of use was assessed against 1997 and 1999 Canadian Consensus Guidelines for IVIG.
Main Results:
- IVIG was used for 90 indications, with only six licensed in Canada.
- Licensed indications accounted for 47% (adult) and 62% (pediatric) of use.
- Despite significant off-label use (53% adult, 38% pediatric), 89% of overall IVIG use was considered appropriate by guidelines. Hematologists and neurologists were the main prescribers.
Conclusions:
- Appropriate off-label utilization of IVIG is prevalent in Canada.
- Current IVIG prescribing practices largely align with established Canadian guidelines.